The Proto-oncogene c-fms Is Overexpressed in Endometrial Cancer

Gary S. Leiserowitz, Steven A. Harris, Malayannan Subramaniam, Gary Keeney, Karl C. Podratz, Thomas C. Spelsberg

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Recent studies have shown that macrophage colony-stimulating factor and its receptor c-fms protein are significantly overexpressed in endometrial and ovarian cancers. In the present study, we analyzed the steady-state levels of c-fms mRNA in benign and malignant endometrial tissues by Northern and slot blot analyses. The relative levels of c-fms mRNA were quantified by using a hybridization signal for each sample on Northern blot analysis. Slot blot analysis was used to further quantitate the relative increase in c-fms mRNA in malignant specimens compared to benign specimens. Correlation of c-fms expression in the endometrial cancers was made with traditional prognostic indicators. Secretory endometrium had low levels of c-fms mRNA, whereas the endometrial cancers had the highest levels. Proliferative and hyperplastic endometrium values were intermediate. Comparative assessment of c-fms expression in endometrial cancer relative to other prognostic factors demonstrated greater expression of c-fms in specimens from patients with abnormal DNA ploidy, high-grade lesions, and possibly extrauterine metastases. Our study confirms the overexpression of c-fms in endometrial cancer and demonstrates a positive correlation between the steady-state mRNA levels of c-fms and other select adverse prognostic indicators.

Original languageEnglish (US)
Pages (from-to)190-196
Number of pages7
JournalGynecologic Oncology
Volume49
Issue number2
DOIs
StatePublished - May 1993

Fingerprint

fms Genes
Endometrial Neoplasms
Messenger RNA
Macrophage Colony-Stimulating Factor Receptors
Endometrium
Northern Blotting
Ploidies
Ovarian Neoplasms
Neoplasm Metastasis
DNA

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Leiserowitz, G. S., Harris, S. A., Subramaniam, M., Keeney, G., Podratz, K. C., & Spelsberg, T. C. (1993). The Proto-oncogene c-fms Is Overexpressed in Endometrial Cancer. Gynecologic Oncology, 49(2), 190-196. https://doi.org/10.1006/gyno.1993.1106

The Proto-oncogene c-fms Is Overexpressed in Endometrial Cancer. / Leiserowitz, Gary S.; Harris, Steven A.; Subramaniam, Malayannan; Keeney, Gary; Podratz, Karl C.; Spelsberg, Thomas C.

In: Gynecologic Oncology, Vol. 49, No. 2, 05.1993, p. 190-196.

Research output: Contribution to journalArticle

Leiserowitz, GS, Harris, SA, Subramaniam, M, Keeney, G, Podratz, KC & Spelsberg, TC 1993, 'The Proto-oncogene c-fms Is Overexpressed in Endometrial Cancer', Gynecologic Oncology, vol. 49, no. 2, pp. 190-196. https://doi.org/10.1006/gyno.1993.1106
Leiserowitz GS, Harris SA, Subramaniam M, Keeney G, Podratz KC, Spelsberg TC. The Proto-oncogene c-fms Is Overexpressed in Endometrial Cancer. Gynecologic Oncology. 1993 May;49(2):190-196. https://doi.org/10.1006/gyno.1993.1106
Leiserowitz, Gary S. ; Harris, Steven A. ; Subramaniam, Malayannan ; Keeney, Gary ; Podratz, Karl C. ; Spelsberg, Thomas C. / The Proto-oncogene c-fms Is Overexpressed in Endometrial Cancer. In: Gynecologic Oncology. 1993 ; Vol. 49, No. 2. pp. 190-196.
@article{68c6f64b4dd9473fabd68fc93e3b8a9b,
title = "The Proto-oncogene c-fms Is Overexpressed in Endometrial Cancer",
abstract = "Recent studies have shown that macrophage colony-stimulating factor and its receptor c-fms protein are significantly overexpressed in endometrial and ovarian cancers. In the present study, we analyzed the steady-state levels of c-fms mRNA in benign and malignant endometrial tissues by Northern and slot blot analyses. The relative levels of c-fms mRNA were quantified by using a hybridization signal for each sample on Northern blot analysis. Slot blot analysis was used to further quantitate the relative increase in c-fms mRNA in malignant specimens compared to benign specimens. Correlation of c-fms expression in the endometrial cancers was made with traditional prognostic indicators. Secretory endometrium had low levels of c-fms mRNA, whereas the endometrial cancers had the highest levels. Proliferative and hyperplastic endometrium values were intermediate. Comparative assessment of c-fms expression in endometrial cancer relative to other prognostic factors demonstrated greater expression of c-fms in specimens from patients with abnormal DNA ploidy, high-grade lesions, and possibly extrauterine metastases. Our study confirms the overexpression of c-fms in endometrial cancer and demonstrates a positive correlation between the steady-state mRNA levels of c-fms and other select adverse prognostic indicators.",
author = "Leiserowitz, {Gary S.} and Harris, {Steven A.} and Malayannan Subramaniam and Gary Keeney and Podratz, {Karl C.} and Spelsberg, {Thomas C.}",
year = "1993",
month = "5",
doi = "10.1006/gyno.1993.1106",
language = "English (US)",
volume = "49",
pages = "190--196",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - The Proto-oncogene c-fms Is Overexpressed in Endometrial Cancer

AU - Leiserowitz, Gary S.

AU - Harris, Steven A.

AU - Subramaniam, Malayannan

AU - Keeney, Gary

AU - Podratz, Karl C.

AU - Spelsberg, Thomas C.

PY - 1993/5

Y1 - 1993/5

N2 - Recent studies have shown that macrophage colony-stimulating factor and its receptor c-fms protein are significantly overexpressed in endometrial and ovarian cancers. In the present study, we analyzed the steady-state levels of c-fms mRNA in benign and malignant endometrial tissues by Northern and slot blot analyses. The relative levels of c-fms mRNA were quantified by using a hybridization signal for each sample on Northern blot analysis. Slot blot analysis was used to further quantitate the relative increase in c-fms mRNA in malignant specimens compared to benign specimens. Correlation of c-fms expression in the endometrial cancers was made with traditional prognostic indicators. Secretory endometrium had low levels of c-fms mRNA, whereas the endometrial cancers had the highest levels. Proliferative and hyperplastic endometrium values were intermediate. Comparative assessment of c-fms expression in endometrial cancer relative to other prognostic factors demonstrated greater expression of c-fms in specimens from patients with abnormal DNA ploidy, high-grade lesions, and possibly extrauterine metastases. Our study confirms the overexpression of c-fms in endometrial cancer and demonstrates a positive correlation between the steady-state mRNA levels of c-fms and other select adverse prognostic indicators.

AB - Recent studies have shown that macrophage colony-stimulating factor and its receptor c-fms protein are significantly overexpressed in endometrial and ovarian cancers. In the present study, we analyzed the steady-state levels of c-fms mRNA in benign and malignant endometrial tissues by Northern and slot blot analyses. The relative levels of c-fms mRNA were quantified by using a hybridization signal for each sample on Northern blot analysis. Slot blot analysis was used to further quantitate the relative increase in c-fms mRNA in malignant specimens compared to benign specimens. Correlation of c-fms expression in the endometrial cancers was made with traditional prognostic indicators. Secretory endometrium had low levels of c-fms mRNA, whereas the endometrial cancers had the highest levels. Proliferative and hyperplastic endometrium values were intermediate. Comparative assessment of c-fms expression in endometrial cancer relative to other prognostic factors demonstrated greater expression of c-fms in specimens from patients with abnormal DNA ploidy, high-grade lesions, and possibly extrauterine metastases. Our study confirms the overexpression of c-fms in endometrial cancer and demonstrates a positive correlation between the steady-state mRNA levels of c-fms and other select adverse prognostic indicators.

UR - http://www.scopus.com/inward/record.url?scp=0027280804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027280804&partnerID=8YFLogxK

U2 - 10.1006/gyno.1993.1106

DO - 10.1006/gyno.1993.1106

M3 - Article

C2 - 8504987

AN - SCOPUS:0027280804

VL - 49

SP - 190

EP - 196

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -